JP2010510171A - ウイルス感染症の治療のための併用療法 - Google Patents
ウイルス感染症の治療のための併用療法 Download PDFInfo
- Publication number
- JP2010510171A JP2010510171A JP2009525739A JP2009525739A JP2010510171A JP 2010510171 A JP2010510171 A JP 2010510171A JP 2009525739 A JP2009525739 A JP 2009525739A JP 2009525739 A JP2009525739 A JP 2009525739A JP 2010510171 A JP2010510171 A JP 2010510171A
- Authority
- JP
- Japan
- Prior art keywords
- antiviral agent
- interferon
- period
- compound
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83887206P | 2006-08-21 | 2006-08-21 | |
US87449806P | 2006-12-13 | 2006-12-13 | |
US89430707P | 2007-03-12 | 2007-03-12 | |
PCT/US2007/076435 WO2008063727A2 (en) | 2006-08-21 | 2007-08-21 | Combination therapy for treatment of viral infections |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010510171A true JP2010510171A (ja) | 2010-04-02 |
JP2010510171A5 JP2010510171A5 (US20080131398A1-20080605-C00009.png) | 2010-10-14 |
Family
ID=39426663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009525739A Pending JP2010510171A (ja) | 2006-08-21 | 2007-08-21 | ウイルス感染症の治療のための併用療法 |
Country Status (6)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019535667A (ja) * | 2016-10-21 | 2019-12-12 | ウニベルシテ クロード ベルナール リヨン 1 | コロナウイルスに関連した感染症の治療のための抗ウイルス組成物 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080138351A1 (en) * | 2006-08-02 | 2008-06-12 | United Therapeutics Corporation | Liposome treatment of viral infections |
JP2011518124A (ja) * | 2008-03-26 | 2011-06-23 | ユニバーシティ・オブ・オックスフォード | 小胞体ターゲッティングリポソーム |
CN102655746B (zh) * | 2009-02-23 | 2016-08-03 | 联合治疗公司 | 亚氨基糖以及治疗病毒性疾病的方法 |
KR101787434B1 (ko) * | 2009-02-24 | 2017-11-15 | 유나이티드 세러퓨틱스 코오포레이션 | 이미노슈가 및 아레나바이러스성 감염을 치료하는 방법 |
KR20120059447A (ko) | 2009-03-27 | 2012-06-08 | 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 | 콜레스테롤 수준 저하 리포좀 |
US8426445B2 (en) * | 2009-06-12 | 2013-04-23 | United Therapeutics Corporation | Iminosugars and methods of treating bunyaviral and togaviral diseases |
JP5653438B2 (ja) * | 2009-09-04 | 2015-01-14 | ユナイテッド セラピューティクス コーポレイション | オルトミクソウイルス感染の治療方法 |
KR101459530B1 (ko) * | 2009-09-04 | 2014-11-07 | 유나이티드 세러퓨틱스 코오포레이션 | 폭스바이러스 감염의 치료 방법 |
WO2011028779A1 (en) * | 2009-09-04 | 2011-03-10 | United Therapeutics Corporation | Iminosugars and methods of treating filoviral diseases |
IL300955A (en) | 2010-06-03 | 2023-04-01 | Pharmacyclics Llc | (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-H1-pyrazolo[4,3-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1- Indicated for use as a drug to treat chronic lymphocytic leukemia or small lymphocytic lymphoma |
US8569255B2 (en) | 2011-02-02 | 2013-10-29 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Post-exposure therapy of influenza A infections |
EA201490836A1 (ru) | 2011-10-21 | 2014-11-28 | Эббви Инк. | Комбинационное лечение (например, с abt-072 или abt-333) с помощью daa для применения при лечении hcv |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
GB2515941A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
JP2015536950A (ja) | 2012-11-02 | 2015-12-24 | ファーマサイクリックス,インク. | Tecファミリーキナーゼ阻害剤アジュバント療法 |
WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
CN109689063A (zh) | 2016-04-28 | 2019-04-26 | 埃默里大学 | 含有炔烃的核苷酸和核苷治疗组合物及其相关用途 |
US20190191740A1 (en) * | 2016-06-23 | 2019-06-27 | Nutrivert Llc | Methods to Promote Growth and Improve Feed Conversion in Animals |
CN116889649A (zh) | 2018-10-05 | 2023-10-17 | 药物治疗股份有限公司 | 生物制品在制造用于人接受者的移植物中的应用 |
US10883084B2 (en) | 2018-10-05 | 2021-01-05 | Xenotherapeutics, Inc. | Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004527566A (ja) * | 2001-05-03 | 2004-09-09 | ヴィロゲン リミテッド | 抗ウイルス化合物 |
WO2006037227A1 (en) * | 2004-10-06 | 2006-04-13 | Migenix Inc. | Combination anti-viral compositions comprising castanospermine and methods of use |
WO2006050250A2 (en) * | 2004-10-29 | 2006-05-11 | Vertex Pharmaceuticals Incorporated | Dose forms comprising vx-950 and their dosage regimen |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6241704B1 (en) * | 1901-11-22 | 2001-06-05 | Sims Deltec, Inc. | Drug pump systems and methods |
US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
US3760984A (en) * | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
GB1555654A (en) * | 1977-06-25 | 1979-11-14 | Exxon Research Engineering Co | Agricultural burner apparatus |
US4036228A (en) * | 1975-09-11 | 1977-07-19 | Alza Corporation | Osmotic dispenser with gas generating means |
US4016880A (en) * | 1976-03-04 | 1977-04-12 | Alza Corporation | Osmotically driven active agent dispenser |
US4111203A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system with means for improving delivery kinetics of system |
US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
NO154918C (no) * | 1977-08-27 | 1987-01-14 | Bayer Ag | Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin. |
US4203442A (en) * | 1977-08-29 | 1980-05-20 | Alza Corporation | Device for delivering drug to a fluid environment |
DE2834122A1 (de) * | 1978-08-03 | 1980-02-14 | Bayer Ag | Verfahren zur herstellung von 6-amino-6-desoxy-l-sorbose |
US4203440A (en) * | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
DE2853573A1 (de) * | 1978-12-12 | 1980-07-03 | Bayer Ag | Herstellung von n-substituierten derivaten des l-desoxynojirimycins |
US4210139A (en) * | 1979-01-17 | 1980-07-01 | Alza Corporation | Osmotic device with compartment for governing concentration of agent dispensed from device |
US4692147A (en) * | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
US4350155A (en) * | 1980-04-02 | 1982-09-21 | Medtronic, Inc. | Body implantable medical infusion system |
US4311137A (en) * | 1980-04-30 | 1982-01-19 | Sherwood Medical Industries Inc. | Infusion device |
DE3038901A1 (de) * | 1980-10-15 | 1982-05-06 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4531937A (en) * | 1983-01-24 | 1985-07-30 | Pacesetter Systems, Inc. | Introducer catheter apparatus and method of use |
US4725852A (en) * | 1985-05-09 | 1988-02-16 | Burlington Industries, Inc. | Random artificially perturbed liquid apparatus and method |
DE3543999A1 (de) * | 1985-12-13 | 1987-06-19 | Bayer Ag | Hochreine acarbose |
US4865845A (en) * | 1986-03-21 | 1989-09-12 | Alza Corporation | Release rate adjustment of osmotic or diffusional delivery devices |
DE3611841A1 (de) * | 1986-04-09 | 1987-10-15 | Bayer Ag | Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten |
US4861892A (en) * | 1988-02-12 | 1989-08-29 | G. D. Searle & Co. | Method for synthesis of deoxymannojirimycin |
US5017563A (en) * | 1988-06-23 | 1991-05-21 | Merrell Dow Pharmaceuticals Inc. | Castanospermine esters and glycosides |
US4855173A (en) * | 1988-08-11 | 1989-08-08 | Dore Peter B | Repair process for a fibre reinforced structure |
US4910310A (en) * | 1988-10-03 | 1990-03-20 | G. D. Searle & Co. | Synthesis of N-substituted 1,5-dideoxy-1,5-imino-L-fucitol derivatives |
US4894388A (en) * | 1988-12-22 | 1990-01-16 | Monsanto Company | Glycosidase inhibitors and use thereof |
US5011929A (en) * | 1989-05-15 | 1991-04-30 | Monsanto Company | Synthesis of mannojirimycin derivatives |
US5100797A (en) * | 1989-06-27 | 1992-03-31 | Monsanto Company | Fucosidase inhibitors |
US5017704A (en) * | 1989-06-27 | 1991-05-21 | Monsanto Company | Fucosidase inhibitor |
US5043273A (en) * | 1989-08-17 | 1991-08-27 | Monsanto Company | Phosphorylated glycosidase inhibitor prodrugs |
US5112614A (en) * | 1989-09-14 | 1992-05-12 | Alza Corporation | Implantable delivery dispenser |
US4994572A (en) * | 1989-10-12 | 1991-02-19 | Monsanto Company | Synthesis of nojirimycin derivatives |
US4996329A (en) * | 1989-10-20 | 1991-02-26 | Monsanto Company | Derivatives of 1,4-dideoxy-1,4-imino-D-mannitol and a process for their preparation |
US5013842A (en) * | 1990-01-22 | 1991-05-07 | Monsanto Company | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors |
US5151519A (en) * | 1990-05-07 | 1992-09-29 | G. D. Searle & Co. | Process for the preparation of 1,5-(alkylimino)-1,5-dideoxy-d-glucitol and derivatives thereof |
US5234693A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
US5234692A (en) * | 1990-07-11 | 1993-08-10 | Alza Corporation | Delivery device with a protective sleeve |
DK0477160T3 (da) * | 1990-09-20 | 1996-05-20 | Monsanto Co | Fremgangsmåde til fremstilling af N-substitueret 1-deoxynojirimycin |
US5200523A (en) * | 1990-10-10 | 1993-04-06 | Monsanto Company | Synthesis of nojirimycin derivatives |
US5137727A (en) * | 1991-06-12 | 1992-08-11 | Alza Corporation | Delivery device providing beneficial agent stability |
US5401645A (en) * | 1992-03-16 | 1995-03-28 | Monsanto Company | Process for producing n-substituted polyhydroxy nitrogen-containing heterocycles utilizing acetobacteraceae and corynebacterium |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5545143A (en) * | 1993-01-21 | 1996-08-13 | T. S. I. Medical | Device for subcutaneous medication delivery |
US5286877A (en) * | 1993-02-01 | 1994-02-15 | G. D. Searle & Co. | Synthesis of 1,4-dideoxy-1,4-imino-L-arabinitol |
US5399567A (en) * | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
US6037351A (en) * | 1994-01-13 | 2000-03-14 | G. D. Searle & Co. | Method of inhibiting hepatitis B virus |
WO1995022975A1 (en) * | 1994-02-25 | 1995-08-31 | G.D. Searle & Co. | Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus |
US5443450A (en) * | 1994-04-29 | 1995-08-22 | Medtronic, Inc. | Medication delivery device and method of construction |
US5559101A (en) * | 1994-10-24 | 1996-09-24 | Genencor International, Inc. | L-ribofuranosyl nucleosides |
DE19509634C1 (de) * | 1995-03-17 | 1996-03-28 | Fresenius Ag | Implantierbare Infusionspumpe |
US5643207A (en) * | 1995-04-28 | 1997-07-01 | Medtronic, Inc. | Implantable techniques for infusing a therapeutic agent with endogenous bodily fluid |
US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
WO1997027840A1 (en) * | 1996-02-02 | 1997-08-07 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
CZ126799A3 (cs) * | 1996-10-16 | 1999-07-14 | Icn Pharmaceuticals | Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují |
JP4080541B2 (ja) * | 1996-10-18 | 2008-04-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子 |
US20030100532A1 (en) * | 1997-02-14 | 2003-05-29 | Gary S. Jacob | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections |
GB2324223A (en) * | 1997-04-11 | 1998-10-14 | Northern Telecom Ltd | Network management |
US6171276B1 (en) * | 1997-08-06 | 2001-01-09 | Pharmacia & Upjohn Ab | Automated delivery device and method for its operation |
US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
CA2300452C (en) * | 1997-12-22 | 2000-11-28 | Schering Corporation | Orally administrable solid ribavirin dosage forms and process for making them |
US5914128A (en) * | 1997-12-22 | 1999-06-22 | Schering Corporation | Orally administrable solid dosage form |
US6423695B1 (en) * | 1998-01-13 | 2002-07-23 | Ribapharm, Inc. | Cytokine related treatments of disease |
US6689759B1 (en) * | 1998-02-12 | 2004-02-10 | G. D. Searle & Co. | Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy |
ES2281170T3 (es) * | 1998-03-31 | 2007-09-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c. |
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
AU751201B2 (en) * | 1998-09-04 | 2002-08-08 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
US6277830B1 (en) * | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
US6308099B1 (en) * | 1998-11-13 | 2001-10-23 | Intermedics Inc. | Implantable device and programmer system which permits multiple programmers |
EP1165080A2 (en) * | 1999-02-12 | 2002-01-02 | G.D. SEARLE & CO. | Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
US6198966B1 (en) * | 1999-02-26 | 2001-03-06 | Medtronic, Inc. | Recirculating implantable drug delivery system |
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US7256005B2 (en) * | 1999-08-10 | 2007-08-14 | The Chancellor, Masters And Scholars Of The University Of Oxford | Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity |
US20050119310A1 (en) * | 2000-02-14 | 2005-06-02 | Mueller Richard A. | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
CN1994298A (zh) * | 2000-03-29 | 2007-07-11 | 沃泰克斯药物股份有限公司 | 氨基甲酸酯天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途 |
WO2001090070A2 (en) * | 2000-05-23 | 2001-11-29 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
DE10031274A1 (de) * | 2000-06-27 | 2002-01-10 | Bosch Gmbh Robert | Wischarm für Kraftfahrzeuge |
AU2002348971A1 (en) * | 2001-10-12 | 2003-04-28 | Stefana M. Petrescu | Ph-sensitive liposomes for targeted drug delivery |
US7091184B2 (en) * | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
WO2005120479A1 (en) * | 2004-06-09 | 2005-12-22 | Gpc Biotech Ag | Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c |
JP2008509902A (ja) * | 2004-08-13 | 2008-04-03 | ミジェニックス インコーポレイテッド | Hepadnaviridae感染を処置または防止するための組成物および方法 |
US20060194835A1 (en) * | 2005-02-09 | 2006-08-31 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
US20080138351A1 (en) * | 2006-08-02 | 2008-06-12 | United Therapeutics Corporation | Liposome treatment of viral infections |
-
2007
- 2007-08-21 WO PCT/US2007/076435 patent/WO2008063727A2/en active Application Filing
- 2007-08-21 US US11/842,569 patent/US20080131398A1/en not_active Abandoned
- 2007-08-21 JP JP2009525739A patent/JP2010510171A/ja active Pending
- 2007-08-21 EP EP07870157A patent/EP2054076A2/en not_active Withdrawn
- 2007-08-21 CA CA002666814A patent/CA2666814A1/en not_active Abandoned
- 2007-08-21 KR KR1020097005854A patent/KR20090057035A/ko not_active Application Discontinuation
-
2012
- 2012-11-21 US US13/683,036 patent/US20130195798A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004527566A (ja) * | 2001-05-03 | 2004-09-09 | ヴィロゲン リミテッド | 抗ウイルス化合物 |
WO2006037227A1 (en) * | 2004-10-06 | 2006-04-13 | Migenix Inc. | Combination anti-viral compositions comprising castanospermine and methods of use |
WO2006050250A2 (en) * | 2004-10-29 | 2006-05-11 | Vertex Pharmaceuticals Incorporated | Dose forms comprising vx-950 and their dosage regimen |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019535667A (ja) * | 2016-10-21 | 2019-12-12 | ウニベルシテ クロード ベルナール リヨン 1 | コロナウイルスに関連した感染症の治療のための抗ウイルス組成物 |
JP7005611B2 (ja) | 2016-10-21 | 2022-01-27 | ウニベルシテ クロード ベルナール リヨン 1 | コロナウイルスに関連した感染症の治療のための抗ウイルス組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20130195798A1 (en) | 2013-08-01 |
WO2008063727A2 (en) | 2008-05-29 |
CA2666814A1 (en) | 2008-05-29 |
WO2008063727A3 (en) | 2009-01-08 |
EP2054076A2 (en) | 2009-05-06 |
KR20090057035A (ko) | 2009-06-03 |
US20080131398A1 (en) | 2008-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010510171A (ja) | ウイルス感染症の治療のための併用療法 | |
JP5715820B2 (ja) | フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物 | |
US20120232062A1 (en) | Azaindazoles to treat flaviviridae virus infection | |
US9101628B2 (en) | Methods and composition of treating a flaviviridae family viral infection | |
US8975247B2 (en) | Methods and compositions of treating a flaviviridae family viral infection | |
WO2006016930A2 (en) | Methods for treating hcv infection | |
JP2008530124A (ja) | フラビウイルス感染症を処置または予防するための組成物および方法 | |
DE60018273T2 (de) | Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv-therapie | |
KR20110054056A (ko) | 마크로사이클릭 hcv 저해제 및 뉴클레오시드의 상승적 배합물 | |
WO2010031832A2 (en) | Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative | |
US7932267B2 (en) | Use of α-glucosidase inhibitors to treat alphavirus infections | |
US9149463B2 (en) | Methods and compositions of treating a Flaviviridae family viral infection | |
US20070258946A1 (en) | Combination Therapy for Treating Hepatitis C Virus Infection | |
CA2516776A1 (en) | Interferon drug therapy for the treatment of viral diseases and liver fibrosis | |
US20040034206A1 (en) | Combination therapy for RNA virus infections involving ribavirin and IMPDH inhibitors | |
EP1007058A1 (en) | USE OF $i(N)-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTIONS | |
WO2005110455A2 (en) | Combination therapy for treating hepatitis virus infection | |
JP2012520885A (ja) | フラビウイルス科ウイルス感染症を治療する方法および組成物 | |
WO2005062949A2 (en) | Method for treating hepatitis virus infection | |
WO2004078207A1 (en) | Interferon drug therapy for the treatment of viral diseases and liver fibrosis | |
US8940730B2 (en) | Methods and compositions of treating a Flaviviridae family viral infection | |
CN101516389A (zh) | 用于治疗病毒感染的联合治疗 | |
Vermehren et al. | CLONAL ANALYSIS OF MUTATIONS SELECTED IN THE HCV NS3 PROTEASE DOMAIN OF GENOTYPE 1 NONRESPONDERS SEQUENTIALLY TREATED WITH BOCEPREVIR (SCH503034) AND/OR PEGYLATED INTERFERON ALFA-2B (PEG-IFN α-2B): 1592 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100820 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100820 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20100825 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100827 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101001 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130108 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130327 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130403 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130702 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130703 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130924 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140124 |